DURECT saw the highest growth of 0.49% in patent filings and 0.49% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of DURECT‘s patent filings and grants. Buy the databook here.
DURECT has been focused on protecting inventions in European Patent Office(EPO) with four publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 33% of filings. The European Patent Office(EPO), South Korea(KR), United States(US), and Australia(AU) patent Office are among the top ten patent offices where DURECT is filings its patents. Among the top granted patent authorities, DURECT has 33% of its grants in South Korea(KR), 33% in Australia(AU) and 33% in Japan(JP).
DURECT stands in second position with respect to its patent publications among its competitors.
Acute liver failure related patents lead DURECT portfolio followed by cosmetics & toiletries, and skincare
DURECT has highest number of patents in acute liver failure followed by cosmetics & toiletries, skincare, ischemia, and liver diseases. For acute liver failure, nearly 12% of patents were filed and 23% of patents were granted in Q2 2024.
For comprehensive analysis of DURECT's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.